News
BerGenBio ASA: Notice of Extraordinary General Meeting
BerGenBio ASA – Key information related to the rights issue
Announcement of fully underwritten rights issue
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
BerGenBio ASA – Minutes from the annual general meeting 2025
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
BerGenBio ASA: Notice of Annual General Meeting
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients